Polycythemia Vera: Causes, Symptoms, Diagnosis, Treatment, and Prognosis

~Introduction

Polycythemia Vera (PV) is a rare, chronic blood disorder in which the bone marrow produces too many red blood cells. This excess thickens the blood, slowing its flow and increasing the risk of serious complications such as blood clots, heart attack, and stroke. Polycythemia Vera belongs to a group of conditions known as myeloproliferative neoplasms (MPNs)—diseases characterized by abnormal blood cell production.

Although Polycythemia Vera is a lifelong condition with no definitive cure, early diagnosis and proper management can significantly reduce symptoms and complications, allowing many patients to live long and active lives.

~What Is Polycythemia Vera?

Polycythemia Vera is a primary polycythemia, meaning the increased red blood cell production originates in the bone marrow rather than being a response to low oxygen levels. In addition to red blood cells, white blood cells and platelets may also be elevated.

The hallmark feature of PV is thickened blood (hyperviscosity), which impairs circulation and increases clotting risk. Over time, PV may progress to more serious conditions such as myelofibrosis, acute leukemia, or bone marrow failure.

~Causes of Polycythemia Vera

JAK2 Gene Mutation

Nearly 95% of Polycythemia Vera cases are caused by a mutation in the JAK2 (Janus kinase 2) gene, most commonly the JAK2 V617F mutation. This mutation causes bone marrow cells to grow and divide uncontrollably, even without normal growth signals.

Is Polycythemia Vera Hereditary?

PV is not typically inherited. The JAK2 mutation is acquired during a person’s lifetime and is not passed from parents to children.

~Risk Factors

Several factors increase the likelihood of developing Polycythemia Vera:

• Age: Most patients are diagnosed after age 60

• Gender: Slightly more common in men

• Genetic susceptibility: Rare familial cases exist

• Environmental factors: Possible association with radiation exposure

~Symptoms of Polycythemia Vera

Symptoms may develop slowly and vary widely among individuals. Some patients are diagnosed incidentally during routine blood tests.

Common Symptoms

• Headaches

• Dizziness or lightheadedness

• Fatigue

• Blurred vision

• Itching, especially after warm showers (aquagenic pruritus)

• Night sweats

• Unexplained weight loss

Physical Signs

• Reddish or purplish skin tone (plethora)

• Enlarged spleen (splenomegaly)

• High blood pressure

Serious Complications

• Blood clots (deep vein thrombosis, pulmonary embolism)

• Stroke or heart attack

• Bleeding episodes

• Gout due to high uric acid levels

~Diagnosis of Polycythemia Vera

Accurate diagnosis requires a combination of blood tests, genetic testing, and sometimes bone marrow evaluation.

Key Diagnostic Tests

1. Complete Blood Count (CBC)

• Elevated red blood cell count

• Increased hemoglobin and hematocrit

• Often elevated white blood cells and platelets

2. JAK2 Mutation Testing

• Confirms presence of JAK2 V617F or exon 12 mutation

3. Serum Erythropoietin (EPO) Level

• Low EPO levels support a diagnosis of PV

4. Bone Marrow Biopsy

• Hypercellular marrow with increased red cell precursors

• Helps distinguish PV from other MPNs

~Polycythemia Vera vs Secondary Polycythemia

Feature	Polycythemia Vera	Secondary Polycythemia
Cause	Bone marrow disorder	Response to low oxygen
JAK2 mutation	Present	Absent
EPO level	Low	Normal or high
Treatment	Phlebotomy, medication	Treat underlying cause

~Treatment of Polycythemia Vera

The primary goal of treatment is to reduce blood thickness and prevent thrombosis.

Phlebotomy

• First-line therapy for most patients

• Regular removal of blood lowers hematocrit levels

• Target hematocrit: <45% in men, <42% in women

Low-Dose Aspirin

• Reduces clotting risk

• Improves blood flow

• Used in most patients unless contraindicated

Cytoreductive Therapy

Recommended for high-risk patients (age >60 or history of thrombosis):

• Hydroxyurea: Most commonly used medication

• Interferon-alpha: Preferred in younger patients and during pregnancy

• Busulfan: Used in select cases

Targeted Therapy

• Ruxolitinib (JAK inhibitor): Used when hydroxyurea is ineffective or not tolerated

• Reduces symptoms and spleen size

~Lifestyle Management

Patients with Polycythemia Vera can improve outcomes through lifestyle measures:

• Stay well hydrated

• Avoid smoking

• Maintain a healthy weight

• Engage in regular, moderate exercise

• Manage cardiovascular risk factors

~Monitoring and Follow-Up

PV requires lifelong monitoring to detect complications early.

Routine Monitoring Includes

• Regular CBC tests

• Symptom assessment

• Spleen size evaluation

• Monitoring for disease progression

~Disease Progression and Complications

Over time, PV may progress to:

Post-Polycythemia Myelofibrosis

• Scarring of bone marrow

• Anemia and fatigue

• Enlarged spleen

Acute Myeloid Leukemia (AML)

• Rare but serious complication

• Occurs in a small percentage of patients

~Prognosis and Life Expectancy

With modern treatment, the outlook for Polycythemia Vera has improved significantly.

• Median survival: 20+ years

• Many patients live near-normal lifespans

• Prognosis depends on age, treatment response, and complications

Early diagnosis and proper risk-based therapy play a critical role in long-term survival.

~Living With Polycythemia Vera

A PV diagnosis can feel overwhelming, but effective management makes the condition manageable.

Coping and Support

• Educate yourself about the disease

• Maintain regular follow-up appointments

• Seek emotional and psychological support

• Join patient support groups

~Frequently Asked Questions (FAQs)

Is Polycythemia Vera curable?
No, PV is not curable, but it is highly manageable with treatment.

Can Polycythemia Vera turn into cancer?
PV itself is a blood cancer and may rarely progress to leukemia.

Is Polycythemia Vera life-threatening?
It can be if untreated, but treatment greatly reduces risks.

~Conclusion

Polycythemia Vera is a chronic myeloproliferative disorder characterized by excessive red blood cell production and an increased risk of blood clots. While it is a lifelong condition, advances in diagnostic tools and targeted therapies have dramatically improved patient outcomes.

With early diagnosis, appropriate treatment, and regular monitoring, individuals with Polycythemia Vera can maintain a good quality of life and long-term survival.